Novo Nordisk, Novartis Settle on Eve of Victoza Patent Trial

Novo Nordisk AS and Novartis AG’s Sandoz Inc. unit settled a patent-infringement suit over the blockbuster diabetes drug Victoza on the eve of their April bench trial in Delaware federal court, Novo Nordisk confirmed on Tuesday.

The settlement licenses Sandoz to launch its generic version by June 22, 2024, “or earlier under certain circumstances,” a Novo Nordisk spokesperson said.

“This settlement reflects the comprehensive U.S. patent portfolio for liraglutide,” Victoza’s active ingredient, Tomas Haagen, Novo Nordisk’s group general counsel and senior vice president, said in a statement. “Novo Nordisk will continue to defend our broad intellectual property portfolio for innovative ...